Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-013613 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Emily K Ninmer und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery/Division of Surgical Oncology, University of Virginia Health System, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Cancer Vaccines, Poly I-C, Melanoma, Polylysine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UVA Cancer Center, Philanthropic Gift, National Institutes of Health.
Abstract (Originalsprache)
Background
For patients with high-risk melanoma who are unresponsive or intolerant to immune checkpoint inhibitors, cancer vaccines may provide benefit with a favorable toxicity profile. CD4 + T cells provide essential help to dendritic cells (DCs) for optimal CD8 + T cell priming in the antitumor response, and induction of tumor-cognate CD4 + T cell responses may enhance vaccine efficacy. We report on a first-in-human approach to treat patients with high-risk melanoma using a vaccine composed of six non-mutated melanoma-specific helper peptides (6MHP) and a shared mutated BRAF-V600E neoantigen helper peptide (mBRAF) co-administered locally with a TLR3 agonist (poly-ICLC) and agonistic CD40 antibody (CDX-1140).
Methods
Adults with high-risk melanoma arising from cutaneous, mucosal, or ocular primary sites who were rendered clinically free of disease after definitive treatment were enrolled to this nonrandomized phase I/II trial ( NCT04364230 ) designed to assess safety and immunogenicity. Participants received vaccine (6MHP+mBRAF+poly-ICLC) with a dose-escalation allocation of CDX-1140 into the vaccine mixture at one of four dose levels (50, 200, 800, 3000 μg). Vaccines were administered at 3-week intervals for four doses. Primary endpoints were safety and peripheral CD4 + T cell response. Exploratory analysis to characterize the vaccine site microenvironment was performed.
Results
Of 22 eligible participants, 11 (50%) had ocular melanoma. Sixteen (73%) received the maximum CDX-1140 dose. Toxicities were limited to grade 1 or 2 treatment-related adverse events, with no dose-limiting toxicities reported. Peripheral CD4 + T cell responses to 6MHP were found ex vivo in six (27%, 95% CI 11% to 50%), including four with the maximum CDX-1140 dose. One had a durable and persistent T cell response to week 25. T cell responses to mBRAF did not meet criteria for positivity ex vivo, but one participant had a durable response after in vitro stimulation, with expansion of multifunctional Th1-polarized CD4 + T cells. Favorable immune-related changes were observed at the vaccine site, including CDX-1140-mediated increases in mature (DC-LAMP + ) DCs.
Conclusions
The vaccine was safe, well-tolerated, and immunogenic. Optimization of vaccines that include agonistic CD40 antibody is needed to enhance immunogenicity. Induction of a multifunctional CD4 + T cell response to mBRAF supports targeting shared mutated neoantigens with melanoma vaccines. Trial registration number NCT04364230 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery/Division of Surgical Oncology, University of Virginia Health System, Charlottesville, Virginia, USA.
- Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
- Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
- Iovance Biotherapeutics Inc, San Carlos, California, USA.
- Department of Medicine/Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, Virginia, USA.
- Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Förderung
- UVA Cancer Center
- Philanthropic Gift
- National Institutes of Health
- U.S. Department of Defense
Zitieren
APA
Ninmer, E. K., Petroni, G. R., Gastman, B. R., Gaughan, E. M., Isaacs, J. M., Haden, K., Kaur, V., Wages, N. A., Chianese-Bullock, K. A., Smith, K. T., Wright, P., Bryant, J., Dunlap-Brown, M., Engel, J. A., Bekiranov, S., Mauldin, I. S., Truong, T. G., Bullock, T. N. J., & Slingluff, C. L. (2026). Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC). Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013613
Vancouver
Ninmer EK, Petroni GR, Gastman BR, Gaughan EM, Isaacs JM, Haden K, et al. Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC). Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-013613
BibTeX
@article{Ninmer2026,
author = {Ninmer, Emily K and Petroni, Gina R and Gastman, Brian R and Gaughan, Elizabeth M and Isaacs, James M and Haden, Kathleen and Kaur, Varinder and Wages, Nolan A and Chianese-Bullock, Kimberly A and Smith, Kelly T and Wright, Paul and Bryant, Jennifer and Dunlap-Brown, Marya and Engel, Jack A and Bekiranov, Stefan and Mauldin, Ileana S and Truong, Thach-Giao and Bullock, Timothy N J and Slingluff, Craig L},
title = {Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-013613}
}
EUVIMED